Data Exclusivity in Canada: Generic drug maker suit against federal government reaches trial stage

Federal regulations that bar Canada's generic drug makers from copying brand-name products for eight years after patents expire will come under the judicial microscope Tuesday as a two-year-old lawsuit reaches Federal Court.
The generic drug makers want the court to set aside rules that they argue cost consumers $115 million in extra drug costs every year.
Link to full article by Canadian Press Here